Drug Trial Radar · NCT07727395
INtra-arterial AltEplase folloWing successfuL reperfusIoN After mEchanical Thrombectomy
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
416
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- 115 People's HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Ho Chi Minh City Stroke Association
- First posted
- Jul 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NEWLINE trial is a multicenter, randomized, open-label, blinded endpoint (PROBE) trial evaluating whether adjunctive low-dose intra-arterial alteplase administered immediately after successful endovascular thrombectomy improves functional outcomes in adults with acute ischemic stroke due to anterior circulation large vessel occlusion. Eligible participants achieving successful reperfusion (eTICI 2b-3) within 24 hours of symptom onset will be randomized 1:1 to receive intra-arterial alteplase plus standard care or standard care alone. The primary outcome is excellent functional outcome (modified Rankin Scale score 0-1) at 90 days.
Conditions
- Stroke, Acute Ischemic
- Large Vessel Occlusion
- Thrombectomy
Interventions
AlteplaseDrug
Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) administered immediately after successful endovascular thrombectomy in addition to best medical management.
Endovascular thrombectomyDevice
Endovascular thrombectomy performed according to current international and local guidelines using approved endovascular techniques and devices.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale at day 90Time frame: 90 days post treatment
- SAFETY OUTCOME: symptomatic intracerebral hemorrahge (sICH ) rate at 24 hours.Time frame: 24hours post EVT
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Chau Doc General Hospital
An Giang, Vietnam · Recruiting
Kien Giang General Hospital
An Giang, Vietnam · Not yet recruiting
Can Tho Central General Hospital
Can Tho, Vietnam · Recruiting
Da Nang Hospital
Da Nang, Vietnam · Recruiting
Hanoi Medical University Hospital
Hà Nội, Vietnam · Recruiting
Military Hospital 103
Hà Nội, Vietnam · Not yet recruiting
Viet Tiep Friendship Hospital
Haiphong, Vietnam · Recruiting
175 Military Hospital
Ho Chi Minh City, Vietnam · Not yet recruiting
People's Hospital 115
Ho Chi Minh City, Vietnam · Recruiting
Thong Nhat Hospital
Ho Chi Minh City, Vietnam · Recruiting
Thu Duc General Hospital
Ho Chi Minh City, Vietnam · Not yet recruiting
University Medical Center
Ho Chi Minh City, Vietnam · Recruiting
Hue Central Hospital
Huế, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.